We are live on ! Find out more
BA

Birinyi Associates Portfolio holdings

AUM $367M
1-Year Est. Return 25.62%
This Fund
S&P 500
This Quarter Est. Return
+7.62%
1 Year Est. Return
+25.62%
3 Year Est. Return
+102.06%
5 Year Est. Return
+132.51%
10 Year Est. Return
+575.15%
AUM
$363M
AUM Growth
+$15M
Cap. Flow
-$9.09M
Cap. Flow %
-2.5%
Top 10 Hldgs %
74.73%
Holding
62
New
4
Increased
11
Reduced
27
Closed
4

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$3.27M
2
NFLX icon
Netflix
NFLX
+$3.06M
3
BLK icon
Blackrock
BLK
+$1.63M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1M
5
MSFT icon
Microsoft
MSFT
+$639K

Sector Composition

Rank Sector Weight
1 Technology 36.69%
2 Financials 16.59%
3 Consumer Discretionary 16.51%
4 Communication Services 10.09%
5 Consumer Staples 3.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MU icon
51
Micron Technology
MU
$930B
$345K 0.1%
4,100
AIQ icon
52
Global X Artificial Intelligence & Technology ETF
AIQ
$9.35B
$344K 0.09%
8,899
+1,680
+23% +$64.6K
QCOM icon
53
Qualcomm
QCOM
$155B
$307K 0.08%
2,000
SHOP icon
54
Shopify
SHOP
$152B
$266K 0.07%
+2,500
New +$243K
AIG icon
55
American International
AIG
$41.7B
$221K 0.06%
3,031
ORCL icon
56
Oracle
ORCL
$374B
$217K 0.06%
1,300
BLK icon
57
Blackrock
BLK
$169B
-1,719
Closed -$1.63M
MELI icon
58
Mercado Libre
MELI
$95.2B
-147
Closed -$302K

Similar funds

Birinyi Associates's Q4 2024 Portfolio in Review

As of Q4 2024, Birinyi Associates held 62 positions worth $363M, up 4.3% from $348M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Birinyi Associates's Q4 2024 filing shows 4 new, 11 increased, 27 reduced and 4 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 2,075 shares worth $1.48M. The largest sale was Eli Lilly, an estimated $3.27M.

By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 36% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Birinyi Associates's largest Q4 2024 buy was Regeneron Pharmaceuticals: 2,075 shares worth $1.48M.
  • Birinyi Associates added most to Texas Roadhouse in Q4 2024, an estimated $624K increase.
  • Birinyi Associates's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $3.27M.
  • Birinyi Associates fully exited Blackrock in Q4 2024, selling an estimated $1.63M.
  • Birinyi Associates's ten largest holdings make up 75% of its $363M portfolio in Q4 2024.
  • Birinyi Associates opened 4 new positions and closed 4 in Q4 2024.
  • Birinyi Associates's portfolio value rose 4.3% quarter-over-quarter to $363M.

Based on Birinyi Associates's 13F filing for Q4 2024, filed 4 Feb 2025.